Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Heart Failure/chemically induced"'
Autor:
David C. Wheeler, Tom Greene, John J.V. McMurray, Hiddo J.L. Heerspink, Robert D. Toto, Anna Maria Langkilde, Glenn M. Chertow, Bergur V. Stefánsson, Fan Fan Hou, Ricardo Correa-Rotter, Dapa-Ckd Trial Committees, Investigators, Peter Rossing, C. David Sjöström, Niels Jongs
Publikováno v:
Lancet Diabetes & Endocrinology, 9(1), 22-31. ELSEVIER SCIENCE INC
DAPA-CKD Trial Committees and Investigators 2021, ' Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease : a prespecified analysis from the DAPA-CKD trial ', The Lancet Diabetes and Endocrinology, vol. 9, no. 1, pp. 22-31 . https://doi.org/10.1016/S2213-8587(20)30369-7
DAPA-CKD Trial Committees and Investigators 2021, ' Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease : a prespecified analysis from the DAPA-CKD trial ', The Lancet Diabetes and Endocrinology, vol. 9, no. 1, pp. 22-31 . https://doi.org/10.1016/S2213-8587(20)30369-7
Background: Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney, cardiovascular, and mortality outcomes according to presence or ab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a3a1159f26d848e4b231091b2729525
https://research.rug.nl/en/publications/92ee2074-5922-4044-aceb-cfcbddfff59c
https://research.rug.nl/en/publications/92ee2074-5922-4044-aceb-cfcbddfff59c
Autor:
Banke, Ann, Fosbøl, Emil L, Møller, Jacob E, Gislason, Gunnar H, Andersen, Mads, Bernsdorf, Mogens, Jensen, Maj-Britt, Schou, Morten, Ejlertsen, Bent
Publikováno v:
Banke, A, Fosbøl, E L, Møller, J E, Gislason, G H, Andersen, M, Bernsdorf, M, Jensen, M B, Schou, M & Ejlertsen, B 2018, ' Long-term effect of epirubicin on incidence of heart failure in women with breast cancer : Insight from a randomized clinical trial ', European Journal of Heart Failure, vol. 20, no. 10, pp. 1447-1453 . https://doi.org/10.1002/ejhf.1168
Banke, A, Fosbøl, E L, Møller, J E, Gislason, G H, Andersen, M, Bernsdorf, M, Jensen, M-B, Schou, M & Ejlertsen, B 2018, ' Long-term effect of epirubicin on incidence of heart failure in women with breast cancer : insight from a randomized clinical trial ', European Journal of Heart Failure, vol. 20, no. 10, pp. 1447-1453 . https://doi.org/10.1002/ejhf.1168
Banke, A, Fosbøl, E L, Møller, J E, Gislason, G H, Andersen, M, Bernsdorf, M, Jensen, M-B, Schou, M & Ejlertsen, B 2018, ' Long-term effect of epirubicin on incidence of heart failure in women with breast cancer : insight from a randomized clinical trial ', European Journal of Heart Failure, vol. 20, no. 10, pp. 1447-1453 . https://doi.org/10.1002/ejhf.1168
AIMS: Anthracycline-based chemotherapy improves survival in breast cancer patients but is associated with increased risk of heart failure (HF). However, the risk of late-onset HF is debatable and mainly based on observational studies. The aim of this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1c608d7c5329f52e962efa3a4ce41b9c
https://portal.findresearcher.sdu.dk/da/publications/c9dee511-62e0-4f6a-8184-015761f100a1
https://portal.findresearcher.sdu.dk/da/publications/c9dee511-62e0-4f6a-8184-015761f100a1
Autor:
Christian Weber, Sébastien Lenglet, Aurélien Thomas, Michael Horckmans, Estelle Lauer, Sabine Steffens, Daniel Hering, Raquel Guillamat-Prats, Maximilian J. Schloss
Publikováno v:
Cardiovascular research, vol. 115, no. 3, pp. 602-613
Cardiovascular Research
Cardiovascular Research, Vol. 115, No 3 (2019) pp. 602-613
Cardiovascular Research, 115(3), 602-613. Oxford University Press
Cardiovascular Research
Cardiovascular Research, Vol. 115, No 3 (2019) pp. 602-613
Cardiovascular Research, 115(3), 602-613. Oxford University Press
Aims Myocardial infarction (MI) leads to an enhanced release of endocannabinoids and a massive accumulation of neutrophils and monocytes within the ischaemic myocardium. These myeloid cells originate from haematopoietic precursors in the bone marrow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad380123a8c898bbdb72fb5e6061b4dd
https://pubmed.ncbi.nlm.nih.gov/30629130
https://pubmed.ncbi.nlm.nih.gov/30629130
Autor:
Schmidt, Morten, Fosbøl, Emil Loldrup, Torp-Pedersen, Christian, Olsen, Anne-Marie Schjerning, Christensen, Bo, Gislason, Gunnar H
Publikováno v:
Schmidt, M, Fosbøl, E L, Torp-Pedersen, C, Olsen, A-M S, Christensen, B & Gislason, G H 2016, ' Kardiovaskulære risici ved behandling med nonsteroide antiinflammatoriske lægemidler ' Ugeskrift for Laeger, bind 178, nr. 52 .
Schmidt, M, Fosbøl, E L, Torp-Pedersen, C, Olsen, A M S, Christensen, B & Gislason, G H 2016, ' Cardiovascular risks of non-steroidal anti-inflammatory drugs treatment ' Ugeskrift for Laeger, vol. 178, no. 52 .
Schmidt, M, Fosbøl, E L, Torp-Pedersen, C, Olsen, A-M S, Christensen, B & Gislason, G H 2016, ' Kardiovaskulære risici ved behandling med nonsteroide antiinflammatoriske lægemidler ', Ugeskrift for Læger, bind 178, nr. 52 .
Schmidt, M, Fosbøl, E L, Torp-Pedersen, C, Olsen, A M S, Christensen, B & Gislason, G H 2016, ' Cardiovascular risks of non-steroidal anti-inflammatory drugs treatment ' Ugeskrift for Laeger, vol. 178, no. 52 .
Schmidt, M, Fosbøl, E L, Torp-Pedersen, C, Olsen, A-M S, Christensen, B & Gislason, G H 2016, ' Kardiovaskulære risici ved behandling med nonsteroide antiinflammatoriske lægemidler ', Ugeskrift for Læger, bind 178, nr. 52 .
Non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs. Current evidence supports that all NSAIDs increase the risk of heart failure and elevate blood pressure, whereas the risk of thrombotic events varies wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::467146b4ba4fd356ca1d57a01139aa46
https://pure.au.dk/portal/da/publications/kardiovaskulaere-risici-ved-behandling-med-nonsteroide-antiinflammatoriske-laegemidler(78006c52-9b5e-4903-a57b-aa0e25a8f657).html
https://pure.au.dk/portal/da/publications/kardiovaskulaere-risici-ved-behandling-med-nonsteroide-antiinflammatoriske-laegemidler(78006c52-9b5e-4903-a57b-aa0e25a8f657).html
Autor:
Huib N. Caron, Daniel K. L. Cheuk, Leontien C. M. Kremer, Elvira C. van Dalen, Elske Sieswerda, Aleida Postma
Publikováno v:
The Cochrane Library
Sieswerda, E, van Dalen, E C, Postma, A, Cheuk, D K L, Caron, H N & Kremer, L C M 2011, ' Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer ', Cochrane Database of Systematic Reviews, vol. 2011, no. 9, CD008011 . https://doi.org/10.1002/14651858.CD008011.pub2
Cochrane Database Syst Rev
Cheuk, D K L, Sieswerda, E, van Dalen, E C, Postma, A & Kremer, L C M 2016, ' Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer ', Cochrane Database of Systematic Reviews, vol. 2016, no. 8, CD008011 . https://doi.org/10.1002/14651858.CD008011.pub3
Sieswerda, E, van Dalen, E C, Postma, A, Cheuk, D K L, Caron, H N & Kremer, L C M 2011, ' Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer ', Cochrane Database of Systematic Reviews, vol. 2011, no. 9, CD008011 . https://doi.org/10.1002/14651858.CD008011.pub2
Cochrane Database Syst Rev
Cheuk, D K L, Sieswerda, E, van Dalen, E C, Postma, A & Kremer, L C M 2016, ' Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer ', Cochrane Database of Systematic Reviews, vol. 2016, no. 8, CD008011 . https://doi.org/10.1002/14651858.CD008011.pub3
Background Anthracyclines are frequently used chemotherapeutic agents for childhood cancer that can cause cardiotoxicity during and after treatment. Although several medical interventions in adults with symptomatic or asymptomatic cardiac dysfunction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c45560939e87209db5d4090d34afbb8
https://doi.org/10.1002/14651858.cd008011.pub3
https://doi.org/10.1002/14651858.cd008011.pub3
Autor:
Evelyn Wong, Jason W. Busse, Sheyu Li, Jiali Liu, Qunfei Chen, Yingqiang Wang, Ke Deng, Per Olav Vandvik, Longhao Zhang, Gordon H. Guyatt, Lorena P. Rios, Ling Li, Jiantong Shen, Germán Málaga, Xin Sun, Zahra N. Sohani, Pujing Zhao, Shanil Ebrahim, Malgorzata M Bala
Publikováno v:
BMJ (British Medical Journal)
Objectives To examine the association between dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of heart failure or hospital admission for heart failure in patients with type 2 diabetes. Design Systematic review and meta-analysis of randomised a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edaf9f4ab03e13503d6193f82b83f352
https://hdl.handle.net/20.500.12866/5100
https://hdl.handle.net/20.500.12866/5100
Publikováno v:
Cochrane database of systematic reviews (Online). (8)
BackgroundAnthracyclines are frequently used chemotherapeutic agents for childhood cancer that can cause cardiotoxicity during and after treatment. Although several medical interventions in adults with symptomatic or asymptomatic cardiac dysfunction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___01423::c1717d0f7da3413a268a0163d8341a9d
https://research.rug.nl/en/publications/b7a239d0-e413-4ee8-bbfc-ff9ef8d7d4e7
https://research.rug.nl/en/publications/b7a239d0-e413-4ee8-bbfc-ff9ef8d7d4e7
Autor:
Ana Catarina Pinto, Philippe Aftimos, Evandro de Azambuja, Carmen Criscitiello, Felipe Ades, Dimitrios Zardavas
Publikováno v:
Breast, 23 (4
Several breast cancer therapies can lead to cardiovascular toxicity: drugs such anthracyclines can cause permanent damage, anti-HER2 agents may cause transitory and reversible cardiac dysfunction and others, such as those used in endocrine therapy, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cea713bd646ecaad19779531718e5c0
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/183636
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/183636
Autor:
Marie Diaz, Evandro de Azambuja, Andre La Gerche, Gilberto de Castro, Martine Piccart-Gebhart, Carmen Criscitiello, Otto Metzger-Filho, Kamal S Saini
Publikováno v:
Breast cancer research, 14 (3
Breast Cancer Research : BCR
Breast Cancer Research : BCR
The concept of 'targeted' therapies implies that such drugs only act on cells that specifically express the particular target, therefore giving rise to a low incidence of side effects. However, targeted therapies currently approved for the treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f7ab2f48a3210192d330e0156a2c179
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/144328
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/144328
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.